Table 3.

Secondary efficacy outcomes

Outcome Parameter	VKA (n=44)	Rivaroxaban (n=46)	Rivaroxaban and Vitamin K2 (n=42)	P a
Death from any cause, n (%)	32 (72.7)	30 (65.2)	27 (64.3)	0.66
Sudden death, n	5	7	4	0.75
Stroke or systemic embolism, n
Ischemic or uncertain type of stroke	7	4	2	0.20
Hemorrhagic stroke	2	0	0	0.21
Systemic embolism	0	0	0	—
Cardiac disease, n
Acute coronary syndrome	6	9	2	0.12
Symptom-driven revascularization b	2	6	1	0.15
Hospitalization for heart failure	5	2	2	0.47
Symptomatic aortic-valve stenosis	2	0	0	0.21
Death from cardiac cause	5	4	2	0.58
Other vascular disease, n
Symptomatic lower-limb ischemia	20	10	9	0.02
Calciphylaxis	4	2	0	0.14
Bowel ischemia	1	2	2	0.87

^aAccording to Fisher exact test.

^bIncluding acute coronary syndrome.